Mesenchymal Progenitor Cells for the Osteogenic Lineage

Noriaki Ono¹ · Henry M. Kronenberg²

Published online: 16 July 2015
© Springer International Publishing AG 2015

Abstract Mesenchymal progenitors of the osteogenic lineage provide the flexibility for bone to grow and maintain its function and homeostasis. Traditionally, colony-forming unit fibroblasts (CFU-Fs) have been regarded as surrogates for mesenchymal progenitors; however, this definition cannot address the function of these progenitors in their native setting. Transgenic murine models including lineage-tracing technologies based on the *cre-lox* system have proven to be useful in delineating mesenchymal progenitors in their native environment. Although heterogeneity of cell populations of interest marked by a promoter-based approach complicates overall interpretation, an emerging complexity of mesenchymal progenitors has been revealed. Current literatures suggest two distinct types of bone progenitor cells; growth-associated mesenchymal progenitors contribute to explosive growth of bone in early life, whereas bone marrow mesenchymal progenitors contribute to the much slower remodeling process and response to injury that occurs mainly in adulthood. More detailed relationships of these progenitors need to be studied through further experimentation.

Keywords Mesenchymal progenitors · Osteoblasts · Chondrocytes · Bone marrow stromal cells · Mesenchymal stem cells · CFU-F · Lineage-tracing system · *Cre-lox* system · Growth plate

Introduction

The life cycle of an organism is marked by a number of biologically important events, including morphogenesis and development, growth and functional maturation, homeostasis and maintenance of proper architecture and function, and response to injury. The significance of stem and progenitor cells playing major roles in these processes has been emphasized. Stem cells are characterized by two important functions: self-renewal, which is the ability to replicate themselves while maintaining their properties, and multipotency, which is the ability to give rise to multiple types of differentiated cell types. Progenitor cells are their downstream offspring with similar but potentially more limited capabilities. Stem and progenitor cells exist in a tissue-specific manner in each organ and tissue during development and are also present in some organs in adult life. In mammals, stem and progenitor cells are well documented not only in tissues that rapidly turn over, such as blood (hematopoietic stem cells) and skin (epithelial stem cells), but also in tissues with much slower turnover such as skeletal muscle (satellite cells) [1] (reviewed in [2]) and the central nervous system (neural stem cells) (reviewed in [3]). The primary function of “connective” tissues is to support other important tissues or organs; while exhibiting remarkable regenerative capacities in response to injury, their turnover is generally slow. Mesenchymal progenitors (sometimes called as “mesenchymal stem cells”) are found virtually in all connective tissues, such as bone, tendon, ligament, dermis, and dental pulp.

The most intensively studied mesenchymal progenitors are those in bone. The primary functions of bones are to provide

This article is part of the Topical Collection on *Molecular Biology of Adult Stem Cells*

✉ Henry M. Kronenberg
hkronenberg@mgh.harvard.edu
Noriaki Ono
noriono@umich.edu

¹ Department of Orthodontics and Pediatric Dentistry, University of Michigan School of Dentistry, Ann Arbor, MI 48109, USA

² Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA

protection for vital organs and to act as levers whereby muscle contraction leads to movement of the organism. Bone cells also support hematopoiesis in the adjacent marrow [4–6] and secrete hormones that regulate carbohydrate and mineral ion metabolism, as well as male fertility [7] and brain function [8]. Bone growth is substantial in fetal life and early postnatal life. Even after bone growth slows or stops, bone cells turn over continually throughout life and provide substantial capability for repair from injury. In this short review, we will discuss recent advances on the biology of the mesenchymal progenitors of the osteogenic lineage that provide the flexibility for bone to grow, maintain its homeostasis, and conduct repair when necessary. We will focus primarily on mammalian models of bone.

Mesenchymal Progenitor Cells for the Osteogenic Lineage in Adult Life

Colony-Forming Unit Fibroblasts: Perivascular Stromal Cell Populations

The bulk of knowledge on mesenchymal progenitors in adult life has been accumulated based on experiments using human and rodent bone marrow cells, by combining in vitro/ex vivo cell culture approaches and heterotopic transplantation of cultured cells into immunodeficient mice. These mesenchymal progenitors are found in a perivascular location, assuming the morphology resembling adventitial reticular cell on bone marrow sinusoids or pericytes on arterioles [9]. The discovery that bone marrow may include mesenchymal progenitors capable of making bone was almost serendipitously discovered in 1960s; when bulk human bone marrow cells were subcutaneously transplanted into immunodeficient mice, they formed ossicles that included blood cells inside [10]. Later, colony-forming unit fibroblasts (CFU-Fs), which are defined as cells capable of adhering to a plastic culture dish and establishing colonies, were found to be responsible for ectopic ossicle formation after subcutaneous transplantation [11]. These ossicles contain osteoblasts and stromal cells of the donor origin with blood cells of the recipient origin; this finding was strongly indicative of the fact that human adult bone marrow includes mesenchymal stromal progenitors capable of reconstituting bone marrow in a new environment; analogous experiments in rodents yielded similar results. However, these criteria for identifying mesenchymal progenitors did not clarify the location and the properties of these cells in situ, because these cells can be identified only after expansion in cell culture. Therefore, the newer approaches using cell surface markers and cell sorting technologies have been pursued to identify their native locations and to prospectively isolate these cells. Initially, the STRO-1 antibody was used to identify and enrich clonal human bone marrow mesenchymal cells [12]. Further studies [13]

showed that all CFU-Fs were recovered in the CD146⁺ fraction of human bone marrow cells. In addition, these cells were serially transplantable subcutaneously and could generate CD146⁺ cells upon secondary transplantation (indicating self-renewal), thus meeting the criteria of “skeletal stem cells.” Sacchetti et al. also found that adventitial reticular cells lining bone marrow sinusoids in vivo were positive for CD146. Later, another group further demonstrated that CD51(αV integrin)⁺PDGFRα⁺ cells represent a small subset of CD146⁺ cells in human bone marrow with even more enriched colony-forming activity [14]. Therefore, these findings have established the idea that human CFU-Fs are found within perivascular stromal cells and can generate bone and stroma upon ectopic transplantation. Whether these cells represent precursors of osteoblasts formed during normal development or during bone remodeling, or perhaps represent cells that respond to injury, is an important question to answer in the future.

In vivo Insights into Mesenchymal Progenitor Cells: Use of Transgenic Markers and Cell Surface Markers

The use of flow cytometry and of mice engineered to express easily assayable proteins such as green fluorescent protein (GFP) or *E. coli* β-galactosidase has allowed identification of distinct mesenchymal cell types in their native environment. One study showed that PDGFRα⁺Sca1⁺ non-hematopoietic cells (“PαS cells”) reside in the perivascular space in vivo and are highly enriched for CFU-Fs [15]. Further, more importantly, co-transplantation of uncultured GFP⁺ PαS cells with hematopoietic stem cells (HSCs) into irradiated donor resulted in engraftment of GFP⁺ cells in bone marrow: they became osteoblasts, adipocytes, stromal cells, and PαS cells themselves, suggesting their self-renewal in vivo. Interestingly, cultured PαS cells did not have such capability. Further insights into mesenchymal progenitors in adult bone marrow have been accrued as byproducts of studies to investigate the HSC “niche” in adult mouse bone marrow. Cxcl12 (chemokine (C-X-C motif) ligand 12) is a stromal cell-derived factor and a critical regulator of HSCs. One group generated a *Cxcl12*-GFP knock-in allele and noted that perivascular reticular cells adjacent to sinusoids or in the endosteum were particularly positive for GFP expression; they named these cells CAR (Cxcl12-abundant reticular) cells [16]. They further demonstrated that individual CAR cells express high level of the osteogenic transcription factors, *Runx2* and *Osx*, and adipogenic transcription factor *PPARγ*. In addition, ablation of CAR cells significantly impaired the formation of osteoblasts and adipocytes in vitro [16]. The theory that mesenchymal and hematopoietic stem cells form a unique bone marrow niche was proposed in 2010 [17]. These investigators discovered that *Nestin*-GFP was expressed in perivascular stromal cells and was especially bright in pericytes of bone marrow arterioles (Nestin is an

intermediate filament protein and a marker for neural stem cells). These *Nes*-GFP⁺ stromal cells colocalized with HSCs, included all CFU-F activities, and formed self-renewable “mesospheres” that could pass serial heterotopic transplantations. Their group subsequently showed that CD51⁺PDGFR α ⁺ cells constituted a population of *Nes*-GFP⁺ cells enriched for supporting hematopoiesis and exhibiting properties of skeletal progenitors in murine and human cell preparations [14]. Alpha-smooth muscle actin (α SMA) is a marker of pericytes. One group generated α SMA-GFP/Cherry transgenic mice and showed that transgene-expressing cells were associated with microvasculature in bone marrow and periosteum and exhibited trilineage differentiation potential in vitro [18]. Further, another group showed that peri-trabecular stromal cells expressed *Osterix* (*Osx*)-Cherry (*Osx* is an important transcription factor in osteoblast differentiation) [19] and *connective tissue growth factor* (*CTGF*)-GFP [20], and the latter cells appear to behave as mesenchymal progenitors at least in vitro and upon transplantation. Therefore, use of transgenic markers and sophisticated cell surface markers in combination with more traditional in vitro, CFU-F, and transplantation assays has proven to be useful in delineating mesenchymal progenitors in adult bone marrow and revealed an emerging complexity of mesenchymal stromal populations, with subpopulations expressing different genes and residing at different locations of bone marrow.

Further Insights into Mesenchymal Progenitor Cells: Murine Lineage-Tracing System

Much of the work on stem cells in mesenchymal tissues has been derived by the ideas of regenerative medicine. Thus, in vitro expansion and transplantation assays have revealed important stem cell-like properties of cells isolated from tissues. These studies cannot, however, address the function of stem cells in their native setting. To explore such functions of progenitor cells, lineage-tracing technologies have been exploited. Typically, such approaches use the *cre-lox* technology to allow promoter-specified expression of *cre* recombinase. *Cre* then acts on reporter genes driven by ubiquitously expressed promoters that are blocked in protein expression by the presence of sequences that stop continued transcription and translation. These “STOP” sequences are flanked by *lox* sites; thus, the reporter protein is synthesized and expressed only after the action of *cre* recombinase. Typically, the *cre* recombinase is covalently bound to the ligand-binding domain of the estrogen receptor (*creERT*) that has been mutated so that tamoxifen but not estradiol can bind. After tamoxifen administration, the recombinase is active only for about 24 h that tamoxifen is present [21], though, after recombinase action, the reporter gene is continually expressed in that cell and its descendants. This approach has been increasingly used to establish progenitor-descendant relationships in an unperturbed environment. The major challenges

in using this approach result from identifying promoters with expression in a narrow array of desirable cell types, and particularly, promoters without expression in putative descendant cells.

Mendez-Ferrer et al. [17] were the first to use such a system to mark and trace the fate of bone marrow mesenchymal progenitors using this system; the authors used a *Nestin-creERT* transgenic line for this purpose. When they induced recombination in adult mice, no descendant was detectable after a month of chase. However, after 8 months of chase, some descendants of cells marked after *cre* recombinase action became osteoblasts, osteocytes, and chondrocytes [17], although more detailed kinetics of marked cells was not shown in this study. The same group further demonstrated that pericytes of bone marrow arterioles were marked by a *NG2-creERT* line [22]; however, the authors did not analyze the fate of these cells thereafter. Grcevic et al. [18] generated *α SMA-creERT* line and analyzed the fate of these cells. Cells in the primary spongiosa and the periosteum were marked, and their descendants increased over a few weeks during normal bone turnover (they did not examine a longer time of chase in this study) and participated in fracture repair. Whether the cells that participated in fracture repair came from perivascular stromal cells or periosteum was not evident from their data. One group used another inducible promoter, the interferon-inducible *Mx1* promoter, to drive expression of *cre* in response to administration of polyI-polyC; *Mx1-cre* marked bone marrow mesenchymal progenitor cells [23]. *Mx1-cre* marked both mesenchymal stromal and hematopoietic cells in bone marrow; the authors carefully eliminated the possibility of the latter’s contribution by removing them with irradiation and bone marrow transplantation. They found that *Mx1-cre* marked stromal cells included cells that continually, for the life of the mouse, became osteoblasts in normal bone and fracture repair and were intravenously transplantable. These cells, when cultured in vitro, were capable of becoming adipocytes, chondrocytes, and osteoblasts. In contrast, their differentiation was limited to “osteolineage” cells (osteoblasts and stromal cells) in normal bone marrow, highlighting the dichotomy between their multi-cellular fates in vitro and their fates in vivo. Because of the extended mode of induction that the authors used in their study (pIpC injection on every other day for 10 days) and the expression of *Mx1-cre* in both osteoblasts and their precursors, they could not ascertain the location and the precise identity of the cells responsible for continually generating osteoblasts in the native environment.

A number of studies using genetic models in recent years have uncovered more detailed biology of mesenchymal progenitors of the osteolineage; however, heterogeneity of cell populations of interest marked by a promoter-based approach complicate overall interpretation of presented data. This is particularly true in studies using a “constitutively active” version of *cre* recombinase. The fundamental difference of

“constitutively active” *cre* from “inducible” *creERT* should not be overlooked; unlike the latter, the former induces recombination whenever the promoter becomes active (no temporal ‘time’ factor). Therefore, if the promoter is active during early development, the *cre* line inherently marks greater numbers of descendants, rendering overall interpretation more complicated. If that promoter becomes active in other cell types later in development, then the possible relationships between the differing cell types marked by a reporter cannot be delineated. For example, one group showed that, among the “P α S” fraction, CFU-Fs were exclusively found within the *Prx1-cre* targeted fraction. The authors concluded that *Prx1-cre* marks early mesenchymal progenitors in adult bone marrow [24]. While this might be the case, because *Prx1-cre* marks essentially all limb mesenchymal cells and their descendants, the promoter-reporter combination cannot be used to identify mesenchymal precursors by histological techniques. More recently, one group reported that perisinusoidal mesenchymal stromal cells expressing leptin receptor (LepR) was the main source of bone-forming cells in adult mice. They showed that, using a *LepR-cre* knock-in allele, the descendants of *LepR-cre* expressing cells contributed to a large fraction of CFU-Fs, and adult osteoblasts and adipocytes; in addition, these cells were intrafemorally transplantable after sublethal irradiation [25]. Interestingly, LepR⁺ cells differentiated into osteoblasts on the bone surfaces only after 2 months of age; before that, they were in the primary spongiosa and in stromal regions. Because the expression of *LepR-cre* could not be limited in time, however, the authors were limited in their ability to identify *in vivo* the specific precursors of adult osteoblasts and adipocytes.

In summary, we now have substantial evidences that several populations of bone marrow stromal cells behave as “mesenchymal stem cells” when taken out of their native environment. However, the identities of cells that are the precursors of adult stromal, osteoblasts, and adipocytes during postnatal growth and homeostasis in adults need further clarification.

Mesenchymal Progenitor Cells of the Osteogenic Lineage in Development

During early limb development, cells in the lateral plate mesoderm express *Prx1* and serve as precursors of all limb mesenchymal cells. In fact, *Prx1-cre* marks essentially all mesenchymal cells in bone, including osteoblasts, chondrocytes and stromal cells, but not cells in skeletal muscles [26]. Subsequently, mesenchymal condensations within the limb bud determine the domain for future bone, and these cells express *Sox9*. As *Sox9-cre* marks essentially all mesenchymal cells in bone, early cells expressing *Sox9* also serve as precursors for osteoblasts and chondrocytes [27]. These fate-mapping studies indicate that developmental mesenchymal

progenitors arise locally within the bone anlage. Subsequently, cells within condensations express type II collagen (Col2) and differentiate into chondrocytes and further into hypertrophic chondrocytes expressing type X collagen (Col10). Around the same time, cells in the surrounding region, the perichondrium, express Osterix (Osx), a critical transcription factor in osteoblast differentiation. Use of an *Osx-creERT* line demonstrated that Osx⁺ cells in the perichondrium invaded into the cartilage template together with blood vessels and subsequently became osteoblasts and stromal cells inside the ossification center [28]. Cells in the perichondrium also expressed *Nes-GFP*, and these cells were derived from cells within the cartilage template expressing *Col2-cre* [29]. Further studies showed that the Osx⁺ cells in the fetal perichondrium only transiently contributed to bone marrow stroma; in contrast, early postnatal Osx⁺ cells contributed to bone marrow stroma persistently for a very long time [30, 31]. Adult Osx⁺ cells did not have such capability [30]. These findings indicate that Osx⁺ cells at a specific time of development are recruited to a perivascular location in bone marrow and become stromal cells, some of which may later behave as mesenchymal progenitors. The underlying reason for differential expression of Osx in a specific subtype of progenitors at a specific time is unknown and requires further studies. In line with these findings, *Osx-cre* also marks not only osteoblasts and osteocytes but also stromal cells and adipocytes [32, 33], complementing the notion that Osx is expressed in these mesenchymal progenitors sometime during their lineage progression.

Recent lines of evidence suggest that cells marked by the expression of genes expressed in mesenchymal condensations represent the major source for chondrocytes, osteoblasts, and stromal cells populations in the limb. Cells expressing type II collagen (Col2) have been implicated to include osteochondroprogenitors, as conditional gene deletion using *Col2-cre* affects both bone and cartilage [34–36]. One recent study showed that, using an inducible genetic labeling system with multiple transgenes expressed in mesenchymal condensations and early growth cartilage, *Col2-creERT*, *Sox9-creERT* and *Acan-creERT*, marked cells at P3 continued to provide osteoblasts and stromal cells for more than a year [31]. In fact, a majority of osteoblasts, *Cxcl12-GFP*⁺ stromal cells (“CAR cells”) and bone marrow mesenchymal progenitors (CFU-Fs and P α S cells) were derivative of cells marked by *Col2-cre*. Further, another group showed that, using *Col10-cre* and *Acan-creERT*, chondrocytes were the source of osteoblasts in endochondral bones during development and fracture healing [37]. Yet another group showed that, using *Col10-cre* and *Col10-creERT*, hypertrophic chondrocytes could become osteoblasts [38]. Therefore, these recent studies suggest that chondrocytes themselves may also be a source of osteoblasts and stromal cells during endochondral bone ossification. The idea that chondrocytes or cells closely related to them in the growth plate cartilage or its surrounding areas represent a

novel population of developmental mesenchymal progenitors of the osteogenic lineage emphasizes that, during the fetal and early postnatal period of comparatively explosive increase in the number of osteolineage cells, multiple cell types are enlisted to form bone. More recently, one group showed that “mouse skeletal stem cells (mSSCs),” which could generate bone, cartilage, and stroma upon transplantation, could be identified by a combination of cell surface markers and found in proximity to the growth plate [39]. Another group showed that, using *Grem1-creER* (Gremlin 1 is an antagonist for bone morphogenic protein, BMP), osteochondroreticular (OCR) stem cells were concentrated within the metaphysis of long bones, but not in the perisinusoidal space [40]; in addition, they showed that these “OCR stem cells” were more clonogenic than perisinusoidal “MSCs.” This pair of studies, more strikingly, took advantage of multicolor *Brainbow* or *Confetti* reporter alleles and elegantly demonstrated the existence of clonogenic precursors in the growth plate region. While *Grem1-creERT* marked early cells that become chondrocytes and osteoblasts in vivo, the transgene did not mark adipocytes, illustrating further the variable fates of cells capable of generating multiple mesenchymal lineages.

Conclusion

In this short review, we have discussed recent advances in our knowledge on mesenchymal progenitor cells of osteogenic cells both in adult life and development. It is increasingly evident that there are two distinct types of bone progenitor cells. Growth-associated mesenchymal progenitors are found in proximity to the growth plate cartilage in the metaphysis and epiphysis of endochondral bones and contribute to explosive growth of bone in early life. In contrast, heterogeneous bone marrow mesenchymal progenitors are found in perisinusoidal locations and contribute to the much slower remodeling process and response to injury that occurs mainly in adulthood. Furthermore, growth-associated mesenchymal progenitors may be eventually recruited to perivascular locations and thus serve as the source of bone marrow mesenchymal progenitors in adult life. More detailed mechanisms on this transition need to be studied through further experimentation.

Compliance with Ethics Guidelines

Conflict of Interest Noriaki Ono and Henry M. Kronenberg declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent Among cited articles where one of the authors of the current report were authors, Local Institutional Review Board approval was obtained and maintained for studies where human (or animal) subjects research was performed.

References

1. Fry CS, Lee JD, Mula J, Kirby TJ, Jackson JR, Liu F, et al. Inducible depletion of satellite cells in adult, sedentary mice impairs muscle regenerative capacity without affecting sarcopenia. *Nat Med*. 2015;21(1):76–80.
2. Brack AS, Rando TA. Tissue-specific stem cells: lessons from the skeletal muscle satellite cell. *Cell Stem Cell*. 2012;10(5):504–14.
3. Goldman SA, Chen Z. Perivascular instruction of cell genesis and fate in the adult brain. *Nat Neurosci*. 2011;14(11):1382–9.
4. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. *Nature*. 2003;425(6960):841–6.
5. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, et al. Identification of the haematopoietic stem cell niche and control of the niche size. *Nature*. 2003;425(6960):836–41.
6. Vrsnjic D, Kalajic Z, Rowe DW, Katavic V, Lorenzo J, Aguila HL. Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. *Blood*. 2004;103(9):3258–64.
7. Oury F, Ferron M, Huizhen W, Confavreux C, Xu L, Lacombe J, et al. Osteocalcin regulates murine and human fertility through a pancreas-bone-testis axis. *J Clin Invest*. 2013;123(6):2421–33.
8. Oury F, Khirman L, Denny CA, Gardin A, Chamouni A, Goeden N, et al. Maternal and offspring pools of osteocalcin influence brain development and functions. *Cell*. 2013;155(1):228–41.
9. Bianco P. “Mesenchymal” stem cells. *Annu Rev Cell Dev Biol*. 2014;30:677–704.
10. Friedenstein AJ, Piatetzky-Shapiro II, Petrakova KV. Osteogenesis in transplants of bone marrow cells. *J Embryol Exp Morphol*. 1966;16(3):381–90.
11. Castro-Malaspina H, Gay RE, Resnick G, Kapoor N, Meyers P, Chiarieri D, et al. Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. *Blood*. 1980;56(2):289–301.
12. Shi S, Gronthos S. Perivascular niche of postnatal mesenchymal stem cells in human bone marrow and dental pulp. *J Bone Miner Res*. 2003;18(4):696–704.
13. Sacchetti B, Funari A, Michienzi S, Di Cesare S, Piersanti S, Saggio I, et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. *Cell*. 2007;131(2):324–36.
14. Pinho S, Lacombe J, Hanoun M, Mizoguchi T, Bruns I, Kunisaki Y, et al. PDGFRalpha and CD51 mark human nestin+ sphere-forming mesenchymal stem cells capable of hematopoietic progenitor cell expansion. *J Exp Med*. 2013;210(7):1351–67.
15. Morikawa S, Mabuchi Y, Kubota Y, Nagai Y, Niiibe K, Hiratsu E, et al. Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. *J Exp Med*. 2009;206(11):2483–96.
16. Omatsu Y, Sugiyama T, Kohara H, Kondoh G, Fujii N, Kohno K, et al. The essential functions of adipo-osteogenic progenitors as the hematopoietic stem and progenitor cell niche. *Immunity*. 2010;33(3):387–99.
17. Mendez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, MacArthur BD, Lira SA, et al. Mesenchymal and hematopoietic stem cells form a unique bone marrow niche. *Nature*. 2010;466(7308):829–34.
18. Grcevic D, Pejda S, Matthews BG, Repic D, Wang L, Li H, et al. In vivo fate mapping identifies mesenchymal progenitor cells. *Stem Cells*. 2012;30(2):187–96.
19. Strecker S, Fu Y, Liu Y, Maye P. Generation and characterization of Osterix-Cherry reporter mice. *Genesis*. 2013;51(4):246–58.
20. Wang W, Strecker S, Liu Y, Wang L, Assanah F, Smith S, et al. Connective tissue growth factor reporter mice label a subpopulation

- of mesenchymal progenitor cells that reside in the trabecular bone region. *Bone*. 2015;71:76–88.
21. Danielian PS, Muccino D, Rowitch DH, Michael SK, McMahon AP. Modification of gene activity in mouse embryos in utero by a tamoxifen-inducible form of Cre recombinase. *Curr Biol*. 1998;8(24):1323–6.
 22. Kunisaki Y, Bruns I, Scheiermann C, Ahmed J, Pinho S, Zhang D, et al. Arteriolar niches maintain haematopoietic stem cell quiescence. *Nature*. 2013;502(7473):637–43.
 23. Park D, Spencer JA, Koh BI, Kobayashi T, Fujisaki J, Clemens TL, et al. Endogenous bone marrow MSCs are dynamic, fate-restricted participants in bone maintenance and regeneration. *Cell Stem Cell*. 2012;10(3):259–72.
 24. Greenbaum A, Hsu YM, Day RB, Schuettpelz LG, Christopher MJ, Borgerding JN, et al. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. *Nature*. 2013;495(7440):227–30.
 25. Zhou BO, Yue R, Murphy MM, Peyer JG, Morrison SJ. Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. *Cell Stem Cell*. 2014.
 26. Logan M, Martin JF, Nagy A, Lobe C, Olson EN, Tabin CJ. Expression of Cre Recombinase in the developing mouse limb bud driven by a *Px1* enhancer. *Genesis*. 2002;33(2):77–80.
 27. Akiyama H, Kim JE, Nakashima K, Balmes G, Iwai N, Deng JM, et al. Osteo-chondroprogenitor cells are derived from *Sox9* expressing precursors. *Proc Natl Acad Sci U S A*. 2005;102(41):14665–70.
 28. Maes C, Kobayashi T, Selig MK, Torrekens S, Roth SI, Mackem S, et al. Osteoblast precursors, but not mature osteoblasts, move into developing and fractured bones along with invading blood vessels. *Dev Cell*. 2010;19(2):329–44.
 29. Ono N, Ono W, Mizoguchi T, Nagasawa T, Frenette PS, Kronenberg HM. Vasculature-associated cells expressing nestin in developing bones encompass early cells in the osteoblast and endothelial lineage. *Dev Cell*. 2014;29(3):330–9.
 30. Mizoguchi T, Ahmed J, Kunisaki Y, Pinho S, Ono N, Kronenberg HM, et al. Osterix marks distinct waves of primitive and definitive stromal progenitors during bone marrow development. *Dev Cell*. (this issue). 2014.
 31. Ono N, Ono W, Nagasawa T, Kronenberg HM. A subset of chondrogenic cells provides early mesenchymal progenitors in growing bones. *Nat Cell Biol*. 2014;16(12).
 32. Liu Y, Strecker S, Wang L, Kronenberg MS, Wang W, Rowe DW, et al. Osterix-cre labeled progenitor cells contribute to the formation and maintenance of the bone marrow stroma. *PLoS One*. 2013;8(8):e71318.
 33. Chen J, Shi Y, Regan J, Karuppaiah K, Ornitz DM, Long F. *Osx*-Cre targets multiple cell types besides osteoblast lineage in postnatal mice. *PLoS One*. 2014;9(1):e85161.
 34. Wang W, Nyman JS, Ono K, Stevenson DA, Yang X, Eleftheriou F. Mice lacking *Nf1* in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I. *Hum Mol Genet*. 2011;20(20):3910–24.
 35. Jacob AL, Smith C, Partanen J, Ornitz DM. Fibroblast growth factor receptor 1 signaling in the osteo-chondrogenic cell lineage regulates sequential steps of osteoblast maturation. *Dev Biol*. 2006;296(2):315–28.
 36. Ford-Hutchinson AF, Ali Z, Lines SE, Hallgrímsson B, Boyd SK, Jirik FR. Inactivation of *Pten* in osteo-chondroprogenitor cells leads to epiphyseal growth plate abnormalities and skeletal overgrowth. *J Bone Miner Res*. 2007;22(8):1245–59.
 37. Zhou X, von der Mark K, Henry S, Norton W, Adams H, de Crombrughe B. Chondrocytes transdifferentiate into osteoblasts in endochondral bone during development, postnatal growth and fracture healing in mice. *PLoS Genet*. 2014;10(12):e1004820.
 38. Yang L, Tsang KY, Tang HC, Chan D, Cheah KS. Hypertrophic chondrocytes can become osteoblasts and osteocytes in endochondral bone formation. *Proc Natl Acad Sci U S A*. 2014;111(33):12097–102.
 39. Chan CK, Seo EY, Chen JY, Lo D, McArdle A, Sinha R, et al. Identification and specification of the mouse skeletal stem cell. *Cell*. 2015;160(1-2):285–98.
 40. Worthley DL, Churchill M, Compton JT, Tailor Y, Rao M, Si Y, et al. Gremlin 1 identifies a skeletal stem cell with bone, cartilage, and reticular stromal potential. *Cell*. 2015;160(1-2):269–84.